Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa.
We tested intranasal application of anti-Pseudomonas conjugate vaccine in mice. Comparison of immunisation via the intra-muscular versus intranasal routes showed the induction of equivalent levels of specific serum IgG and IgG subclasses antibodies if cholera toxin was used as an adjuvant. In contrast, secretion of specific mucosal IgA antibodies in the upper respiratory tract was only observed after intranasal immunisation together with adjuvant. Systemic and mucosal immunity was also established via the intranasal route when CpG-containing oligonucleotides were used as adjuvant. The functionality of intranasally induced antibodies was proven in vitro by opsonophagocytosis and in vivo using the burn-wound sepsis and intra-tracheal lung infection models. These results demonstrate the feasibility of intranasal immunisation against P. aeruginosa with conjugate vaccine.
Zuercher
Adrian W
AW
Berna Biotech Ltd., Rehhagstrasse 79, CH-3018 Bern, Switzerland.
Horn
Michael P
MP
Wu
Hong
H
Song
Zhijun
Z
Bundgaard
Cathrine J
CJ
Johansen
Helle Krogh
HK
Høiby
Niels
N
Marcus
Paul
P
Lang
Alois B
AB
D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000145:classification / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D011552:Pseudomonas Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification*; D012141:Respiratory Tract Infections / Q000276:immunology / Q000517:prevention & control*
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G